The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics

The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis 2006-02, Vol.12 (1), p.24-38
Hauptverfasser: Minden, S L, Frankel, D, Hadden, L, Perloff, J, Srinath, K P, Hoaglin, D C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 38
container_issue 1
container_start_page 24
container_title Multiple sclerosis
container_volume 12
creator Minden, S L
Frankel, D
Hadden, L
Perloff, J
Srinath, K P
Hoaglin, D C
description The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys.
doi_str_mv 10.1191/135248506ms1262oa
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67635013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_135248506ms1262oa</sage_id><sourcerecordid>970002711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</originalsourceid><addsrcrecordid>eNp10E1v1DAQBmALgWgp_AAuKEKCW4odf8XcUMWXtIjDlguXaDJ2ui5OsniSw_57XO1KK4E42dI8M_a8jL0U_FoIJ94JqRvVam5GEo1pZnjELoWytubO8sflXuq10q2-YM-I7jnn1kr9lF0Io7Szwl6yn7e7UG3n6QDVNsXhF1SbebqLy-rjBKn6tqYl7lMhmEKeKVK1LbXD-2oMy272VMHkK4LxweAOMuAScqQlIj1nTwZIFF6cziv249PH25sv9eb75683HzY1SqeX2oHnDoLtexQKVW8lB6W47xG5B8v70GCQ2hh0KA0K76Q12CMMXtq2N_KKvT3O3ef59xpo6cZIGFKCKcwrdcYaqbmQBb7-C97Pay5rUteItm24lq4gcURY1qUchm6f4wj50AnePaTe_ZN66Xl1Grz2Y_DnjlPMBbw5ASCENGSYMNLZWSVba9riro-O4C6cf_f_l_8AkLCaNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218820539</pqid></control><display><type>article</type><title>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Minden, S L ; Frankel, D ; Hadden, L ; Perloff, J ; Srinath, K P ; Hoaglin, D C</creator><creatorcontrib>Minden, S L ; Frankel, D ; Hadden, L ; Perloff, J ; Srinath, K P ; Hoaglin, D C</creatorcontrib><description>The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1191/135248506ms1262oa</identifier><identifier>PMID: 16459717</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Attitude to Health ; Biological and medical sciences ; Costs and Cost Analysis ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Demography ; Female ; Health Status ; Health Surveys ; Humans ; Immunomodulators ; Interviews as Topic ; Longitudinal Studies ; Male ; Massachusetts ; Medical sciences ; Middle Aged ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - economics ; Multiple Sclerosis - therapy ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Pharmacology. Drug treatments</subject><ispartof>Multiple sclerosis, 2006-02, Vol.12 (1), p.24-38</ispartof><rights>2006 INIST-CNRS</rights><rights>2006 Arnold</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</citedby><cites>FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/135248506ms1262oa$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/135248506ms1262oa$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17438768$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16459717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minden, S L</creatorcontrib><creatorcontrib>Frankel, D</creatorcontrib><creatorcontrib>Hadden, L</creatorcontrib><creatorcontrib>Perloff, J</creatorcontrib><creatorcontrib>Srinath, K P</creatorcontrib><creatorcontrib>Hoaglin, D C</creatorcontrib><title>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Attitude to Health</subject><subject>Biological and medical sciences</subject><subject>Costs and Cost Analysis</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Demography</subject><subject>Female</subject><subject>Health Status</subject><subject>Health Surveys</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Interviews as Topic</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Massachusetts</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - economics</subject><subject>Multiple Sclerosis - therapy</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp10E1v1DAQBmALgWgp_AAuKEKCW4odf8XcUMWXtIjDlguXaDJ2ui5OsniSw_57XO1KK4E42dI8M_a8jL0U_FoIJ94JqRvVam5GEo1pZnjELoWytubO8sflXuq10q2-YM-I7jnn1kr9lF0Io7Szwl6yn7e7UG3n6QDVNsXhF1SbebqLy-rjBKn6tqYl7lMhmEKeKVK1LbXD-2oMy272VMHkK4LxweAOMuAScqQlIj1nTwZIFF6cziv249PH25sv9eb75683HzY1SqeX2oHnDoLtexQKVW8lB6W47xG5B8v70GCQ2hh0KA0K76Q12CMMXtq2N_KKvT3O3ef59xpo6cZIGFKCKcwrdcYaqbmQBb7-C97Pay5rUteItm24lq4gcURY1qUchm6f4wj50AnePaTe_ZN66Xl1Grz2Y_DnjlPMBbw5ASCENGSYMNLZWSVba9riro-O4C6cf_f_l_8AkLCaNw</recordid><startdate>20060201</startdate><enddate>20060201</enddate><creator>Minden, S L</creator><creator>Frankel, D</creator><creator>Hadden, L</creator><creator>Perloff, J</creator><creator>Srinath, K P</creator><creator>Hoaglin, D C</creator><general>SAGE Publications</general><general>Arnold</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20060201</creationdate><title>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</title><author>Minden, S L ; Frankel, D ; Hadden, L ; Perloff, J ; Srinath, K P ; Hoaglin, D C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-9ad09ae7bbc14c4b730a440dbcc0da70be2ce3566c9c36c1d9376cbcafd378b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Attitude to Health</topic><topic>Biological and medical sciences</topic><topic>Costs and Cost Analysis</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Demography</topic><topic>Female</topic><topic>Health Status</topic><topic>Health Surveys</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Interviews as Topic</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Massachusetts</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - economics</topic><topic>Multiple Sclerosis - therapy</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minden, S L</creatorcontrib><creatorcontrib>Frankel, D</creatorcontrib><creatorcontrib>Hadden, L</creatorcontrib><creatorcontrib>Perloff, J</creatorcontrib><creatorcontrib>Srinath, K P</creatorcontrib><creatorcontrib>Hoaglin, D C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minden, S L</au><au>Frankel, D</au><au>Hadden, L</au><au>Perloff, J</au><au>Srinath, K P</au><au>Hoaglin, D C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2006-02-01</date><risdate>2006</risdate><volume>12</volume><issue>1</issue><spage>24</spage><epage>38</epage><pages>24-38</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>The Sonya Slifka Longitudinal Multiple Sclerosis Study follows a population-based cohort of approximately 2000 people with multiple sclerosis (MS) to study demographic and clinical characteristics, course of illness, utilization and cost of health services, provider characteristics, use of MS specialists and disease modifying agents, and neurologic, economic and psychosocial outcomes. This report describes the study methodology, presents baseline demographic and clinical data, and evaluates the representativeness of the sample. A stratified random sample of persons with established and recently-diagnosed MS selected from the National Multiple Sclerosis Society (NMSS) mailing lists was supplemented with recently-diagnosed patients recruited through systematic nationwide outreach. Baseline data were collected by computer-assisted telephone interviews derived from standardized instruments; data collection continues at six-month intervals. The cohort was comparable to population-based and clinical samples with respect to demographics, course, relapse rate, symptoms, and severity of disability. Almost two-thirds of the cohort needed help with activities of daily living, three-quarters were limited in work or other activities, and half had emotional problems that compromised quality of life. The Slifka Study cohort is broadly representative of the MS population and the database can be used to address questions not answered by natural history studies, clinical databases, or population-based surveys.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>16459717</pmid><doi>10.1191/135248506ms1262oa</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1352-4585
ispartof Multiple sclerosis, 2006-02, Vol.12 (1), p.24-38
issn 1352-4585
1477-0970
language eng
recordid cdi_proquest_miscellaneous_67635013
source Access via SAGE; MEDLINE
subjects Adolescent
Adult
Aged
Aged, 80 and over
Attitude to Health
Biological and medical sciences
Costs and Cost Analysis
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Demography
Female
Health Status
Health Surveys
Humans
Immunomodulators
Interviews as Topic
Longitudinal Studies
Male
Massachusetts
Medical sciences
Middle Aged
Multiple Sclerosis - diagnosis
Multiple Sclerosis - economics
Multiple Sclerosis - therapy
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Pharmacology. Drug treatments
title The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A22%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Sonya%20Slifka%20Longitudinal%20Multiple%20Sclerosis%20Study:%20methods%20and%20sample%20characteristics&rft.jtitle=Multiple%20sclerosis&rft.au=Minden,%20S%20L&rft.date=2006-02-01&rft.volume=12&rft.issue=1&rft.spage=24&rft.epage=38&rft.pages=24-38&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1191/135248506ms1262oa&rft_dat=%3Cproquest_cross%3E970002711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218820539&rft_id=info:pmid/16459717&rft_sage_id=10.1191_135248506ms1262oa&rfr_iscdi=true